The table below lists the status of prioritized health technologies for HTA. Prioritized topics refer to health technologies that adhered to HTAC’s standard set of criteria responding to the priority health care needs of the country.
Definitions of each status:
- Assessment refers to the application of formal scientific methods of evidence synthesis to assess the clinical, economic, health system, ethical, legal and social impact of covering or disinvesting a particular health technology in the local Philippine context.
- Initial findings of the Assessment for Public Consultation refers to the key findings of the Assessment, which will be available for public consultation.
- Preliminary Recommendation refers to the initial recommendation issued by HTAC through a deliberative process of assessing the quality and the strength of the evidence guided by a decision framework aligned with the UHC law. Preliminary recommendation is made based on the results of the Assessment, and the inputs of stakeholders during the public consultation. After its release, the preliminary recommendation shall be open for appeals. Appeals refers to the process where all stakeholders are allowed to submit any comments, appeals, or requests for reconsideration within 10 working days based on any of the following grounds:
-
- Not all relevant evidence has been considered by HTAC
- New additional evidence that could influence the recommendation of HTAC
- A new price offer from the manufacturer of the product to ensure its affordability to DOH and PHIC.
-
- Final Recommendation refers to the recommendation by HTAC upon consideration of appeals on a particular health technology.
- Decision refers to the process of decision-making based on transmitted recommendation of the HTAC to the Secretary of Health and the PHIC Board of Directors for health interventions that are within their remit. The Secretary of Health and the PHIC Board of Directors shall provide an issuance in response to the transmitted recommendation of HTAC.
Note: In the event of a declared Public Health Emergency (e.g., COVID-19), status of health technologies (i.e., those that potentially respond to the said health emergency) will only be Assessment, Recommendation, and Decision. The Philippine HTA Process Guide elaborates both HTA processes during normal circumstances and during Public Health Emergencies.
COVID-19 technologies
Name of health technology | Type of health technology | Assessment Status | Recommendation Status | Decision Status |
---|---|---|---|---|
Rapid antibody tests (RATs)(May 2020 reassessment) | Clinical equipment and devices | Complete | Complete | Available |
Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) | Clinical equipment and devices | Complete | Complete | Available |
AMTI uAI-Discover-PNA | Clinical equipment and devices | Complete | Complete | Available |
Favipiravir | Drugs | Complete | Complete | Available |
Cycloferon | Drugs | Complete | Complete | Available |
Huawei Cloud AI-Assisted Diagnosis | Clinical equipment and devices | Complete | Complete | Available |
Rapid antibody tests (RATs)(March 2020 assessment) | Clinical equipment and devices | Complete | Complete | Available |
Use of Pooled Testing for the diagnosis, screening and surveillance of COVID-19 | Clinical equipment and devices | Complete | Complete | Available |
Use of Rapid Antigen test kits for the diagnosis of COVID-19 | Clinical equipment and devices | Complete | Complete | Available |
Extracorporeal Membrane Oxygenation (ECMO) for COVID-19 patients with ARDS | Clinical equipment and devices, Medical and surgical procedures | Complete | Complete | Available |
High-Flow Nasal Cannula Oxygen Therapy for the treatment of Acute Hypoxemic Respiratory Failure for COVID-19 | Clinical equipment and devices, Medical and surgical procedures | Complete | Complete | Available |
COVID-19 Vaccine (ChAdOx1-S [recombinant]) (COVID-19 Vaccine AstraZeneca) for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete | Available |
BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19 | Vaccines, Preventive and promotive health services | Complete | Complete | Available |
Non-COVID-19 technologies
Name of health technology | Type of health technology | Assessment Status | Initial findings of the Assessment for Public Consultation Status | Preliminary Recommendation Status | Final Recommendation Status | Decision Status |
---|---|---|---|---|---|---|
Pneumococcal Conjugate Vaccine 13 (PCV-13)(2020 Reassessment) | Vaccines | Complete | Complete | Complete | Complete | Available |